Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.

Retèl VP, Joore MA, van Harten WH.

Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24.

PMID:
21947677
2.

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.

Retèl VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH.

Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar 30.

PMID:
20359886
3.

Scenario drafting to anticipate future developments in technology assessment.

Retèl VP, Joore MA, Linn SC, Rutgers EJ, van Harten WH.

BMC Res Notes. 2012 Aug 16;5:442. doi: 10.1186/1756-0500-5-442.

4.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.

J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.

PMID:
22966753
5.

Prospective cost-effectiveness analysis of genomic profiling in breast cancer.

Retèl VP, Joore MA, Drukker CA, Bueno-de-Mesquita JM, Knauer M, van Tinteren H, Linn SC, van Harten WH.

Eur J Cancer. 2013 Dec;49(18):3773-9. doi: 10.1016/j.ejca.2013.08.001. Epub 2013 Aug 27.

PMID:
23992641
6.

Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.

Yang M, Rajan S, Issa AM.

Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22.

7.

Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer.

Bonastre J, Marguet S, Lueza B, Michiels S, Delaloge S, Saghatchian M.

J Clin Oncol. 2014 Nov 1;32(31):3513-9. doi: 10.1200/JCO.2013.54.9931. Epub 2014 Oct 6.

PMID:
25287824
8.

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.

Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T.

Breast Cancer Res Treat. 2012 Jun;133(3):1115-23. doi: 10.1007/s10549-012-1989-5. Epub 2012 Feb 24.

PMID:
22361999
9.

Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.

Paulden M, Franek J, Pham B, Bedard PL, Trudeau M, Krahn M.

Value Health. 2013 Jul-Aug;16(5):729-39. doi: 10.1016/j.jval.2013.03.1625. Epub 2013 Jul 1.

10.

Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.

Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M.

Clin Ther. 2010 Feb;32(2):311-26. doi: 10.1016/j.clinthera.2010.01.029.

PMID:
20206789
11.

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.

Seguí MÁ, Crespo C, Cortés J, Lluch A, Brosa M, Becerra V, Chiavenna SM, Gracia A.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Epub 2014 Sep 12.

PMID:
25213317
12.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

13.

Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?

Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL.

Genet Med. 2005 Jul-Aug;7(6):380-9.

PMID:
16024969
14.

Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.

Chen E, Tong KB, Malin JL.

Am J Manag Care. 2010 Dec 1;16(12):e333-42.

15.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

16.
17.

Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?

Naeim A, Keeler EB.

Breast Cancer Res Treat. 2005 Nov;94(2):95-103.

PMID:
16261407
18.

A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease.

Collins R, Cranny G, Burch J, Aguiar-Ibáñez R, Craig D, Wright K, Berry E, Gough M, Kleijnen J, Westwood M.

Health Technol Assess. 2007 May;11(20):iii-iv, xi-xiii, 1-184. Review.

19.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

20.

Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.

El Ouagari K, Karnon J, Delea T, Talbot W, Brandman J.

Breast Cancer Res Treat. 2007 Jan;101(1):37-49. Epub 2006 Jul 4.

PMID:
16821085

Supplemental Content

Support Center